Wanming M. Hu

Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 81 publications

Clinicopathological analysis of primary central nervous system ALK-positive histiocytosis

Clinicopathological analysis of primary central nervous system ALK-positive histiocytosis

Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology

Published: September 07, 2026

Author Correction: A proteogenomic atlas of 1032 brain metastases identifies molecular subtypes, immune landscapes, and therapeutic vulnerabilities.

Author Correction: A proteogenomic atlas of 1032 brain metastases identifies molecular subtypes, immune landscapes, and therapeutic vulnerabilities.

Journal: Nature communications

Published: April 15, 2026

Nanopore-based DNA methylation profiling for rapid molecular classification of NOS/NEC CNS tumors: multi-institutional evaluation using FFPE archives and frozen tissues.

Nanopore-based DNA methylation profiling for rapid molecular classification of NOS/NEC CNS tumors: multi-institutional evaluation using FFPE archives and frozen tissues.

Journal: Acta neuropathologica communications

Published: February 12, 2026

Multifocal EBV-associated smooth muscle tumors: a clinicopathological analysis of seven cases

Multifocal EBV-associated smooth muscle tumors: a clinicopathological analysis of seven cases

Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology

Published: February 05, 2026

Multi-omics profiling identifies HMGA2 fusions as defining a distinct and prognostically favorable subtype of dedifferentiated liposarcoma with rhabdomyosarcomatous differentiation.

Multi-omics profiling identifies HMGA2 fusions as defining a distinct and prognostically favorable subtype of dedifferentiated liposarcoma with rhabdomyosarcomatous differentiation.

Journal: Human pathology

Published: February 05, 2026

A novel BEND2 monoclonal antibody enables highly specific immunohistochemical diagnosis of BEND2-fusion astroblastomas.

A novel BEND2 monoclonal antibody enables highly specific immunohistochemical diagnosis of BEND2-fusion astroblastomas.

Journal: Acta neuropathologica

Published: January 06, 2026

Deep learning-based classification of gh-secreting pituitary neuroendocrine tumors granulation patterns using H&E-stained histopathology.

Deep learning-based classification of gh-secreting pituitary neuroendocrine tumors granulation patterns using H&E-stained histopathology.

Journal: BMC endocrine disorders

Published: December 18, 2025

Feasibility and Tumor Dynamics of Daily MRI-Guided Online Adaptive Radiotherapy for Brain Glioma.

Feasibility and Tumor Dynamics of Daily MRI-Guided Online Adaptive Radiotherapy for Brain Glioma.

Journal: CNS neuroscience & therapeutics

Published: September 30, 2025

A proteogenomic atlas of 1032 brain metastases identifies molecular subtypes, immune landscapes, and therapeutic vulnerabilities.

A proteogenomic atlas of 1032 brain metastases identifies molecular subtypes, immune landscapes, and therapeutic vulnerabilities.

Journal: Nature communications

Published: September 10, 2025

Oncolytic virus M1 reinvigorates CD8+ T-cell immunity against glioblastoma through B-cell-dependent antigen cross-presentation in the spleen.

Oncolytic virus M1 reinvigorates CD8+ T-cell immunity against glioblastoma through B-cell-dependent antigen cross-presentation in the spleen.

Journal: Cellular & molecular immunology

Published: September 03, 2025

Adjuvant radiotherapy for patients with clinical T3-4 oral and oropharyngeal cancer who achieved major pathologic response after neoadjuvant immunochemotherapy and surgery: a propensity score-matched retrospective study.

Adjuvant radiotherapy for patients with clinical T3-4 oral and oropharyngeal cancer who achieved major pathologic response after neoadjuvant immunochemotherapy and surgery: a propensity score-matched retrospective study.

Journal: Frontiers in immunology

Published: August 07, 2025

VAL-083 is effective in patients with newly-diagnosed MGMT-unmethylated glioblastoma: report of phase II study.

VAL-083 is effective in patients with newly-diagnosed MGMT-unmethylated glioblastoma: report of phase II study.

Journal: Discover oncology

Published: July 23, 2025

Showing 1-12 of 81

Last Updated: 09/26/2026